严重急性呼吸综合征冠状病毒2型再感染与体液免疫衰退：一例报告

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.

作者信息

Goldman Jason D, Wang Kai, Röltgen Katharina, Nielsen Sandra C A, Roach Jared C, Naccache Samia N, Yang Fan, Wirz Oliver F, Yost Kathryn E, Lee Ji-Yeun, Chun Kelly, Wrin Terri, Petropoulos Christos J, Lee Inyoul, Fallen Shannon, Manner Paula M, Wallick Julie A, Algren Heather A, Murray Kim M, Hadlock Jennifer, Chen Daniel, Dai Chengzhen L, Yuan Dan, Su Yapeng, Jeharajah Joshua, Berrington William R, Pappas George P, Nyatsatsang Sonam T, Greninger Alexander L, Satpathy Ansuman T, Pauk John S, Boyd Scott D, Heath James R

机构信息

Division of Infectious Diseases, Swedish Medical Center, Seattle, WA 98122, USA.

Providence St. Joseph Health, Renton, WA 98057, USA.

出版信息

Vaccines (Basel). 2022 Dec 20;11(1):5. doi: 10.3390/vaccines11010005.

Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the first cases of reinfection reported in 2020. With antibody, B cell and T cell analytics, we show correlates of adaptive immunity at reinfection, including a differential response in neutralizing antibodies to a D614G pseudovirus. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.

从新冠病毒疾病（COVID-19）中康复与抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的产生有关，但这些抗体是否能提供免疫力尚不确定。我们描述了住院患者的病毒RNA脱落持续时间，并确定了病毒反复脱落的患者。我们对一名患者在间隔144天的两次有症状的COVID-19不同发作期的病毒进行了测序，以确凿地描述感染携带刺突变体D614G的不同毒株导致的再次感染。这例再次感染病例是2020年报告的首批再次感染病例之一。通过抗体、B细胞和T细胞分析，我们展示了再次感染时适应性免疫的相关因素，包括对D614G假病毒的中和抗体的差异反应。最后，我们讨论了对疫苗计划的影响，并开始确定预防SARS-CoV-2再次感染的保护基准。